BIOMAT Database Logo BIOMAT Database Logo

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. 2009

Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA.

Adoptive transfer of antigen-specific cytotoxic T lymphocytes (CTLs) can induce objective clinical responses in patients with malignant diseases. The option of providing a proliferative and survival advantage to adoptively transferred CTLs remains a challenge to improve their efficacy. Host lymphodepletion and administration of recombinant interleukin-2 (IL-2) are currently used to improve CTL survival and expansion after adoptive transfer, but these approaches are frequently associated with significant side effects and may increase proliferation of T regulatory cells. IL-7 is a crucial homeostatic cytokine that has been safely administered as a recombinant protein. However, while IL-7 induces robust expansion of naive and memory T lymphocytes, the lack of expression of the IL-7 receptor alpha chain (IL-7Ralpha) by CTLs precludes their response to this cytokine. We found that CTLs can be genetically modified to re-express IL-7Ralpha, and that this manipulation restores the response of these cells to IL-7 without apparent modification of their antigen specificity or dependency, and without changing their response to other common gamma (gammac) chain cytokines. This approach may allow selective expansion of CTLs without the unwanted effects associated with IL-2.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015851 Interleukin-7 A cytokine produced by bone marrow stromal cells that promotes the growth of B-LYMPHOCYTE precursors and is co-mitogenic with INTERLEUKIN-2 for mature T-LYMPHOCYTE activation. IL-7,IL7,Lymphopoietin-1,Interleukin 7,Lymphopoietin 1
D016513 Mice, SCID Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice. SCID Mice,SCID-hu Mice,Severe Combined Immunodeficient Mice,Immunodeficient Mice, Severe Combined,Mouse, SCID,Mouse, SCID-hu,Mice, SCID-hu,Mouse, SCID hu,SCID Mouse,SCID hu Mice,SCID-hu Mouse
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Allogeneic tumor-specific cytotoxic T lymphocytes.
January 1992, Cancer immunology, immunotherapy : CII,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
[Tumor specific antigen and cytotoxic T lymphocytes].
April 2005, Nihon rinsho. Japanese journal of clinical medicine,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
September 2009, Journal of immunotherapy (Hagerstown, Md. : 1997),
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
July 1994, Behring Institute Mitteilungen,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Tumor-specific autologous cytotoxic T lymphocytes from tissue sections.
December 1996, Nature medicine,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Manipulation of cytotoxic T lymphocyte responses to syngeneic tumors. I. Hapten-reactive helper T lymphocytes augment tumor-specific CTL responses in vitro.
June 1979, Journal of immunology (Baltimore, Md. : 1950),
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation.
June 2004, International journal of cancer,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
HIV-specific cytotoxic T lymphocytes.
January 1989, Research in immunology,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells.
October 2007, International immunology,
Juan F Vera, and Valentina Hoyos, and Barbara Savoldo, and Concetta Quintarelli, and Greta M P Giordano Attianese, and Ann M Leen, and Hao Liu, and Aaron E Foster, and Helen E Heslop, and Cliona M Rooney, and Malcolm K Brenner, and Gianpietro Dotti
Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs).
January 2014, Theranostics,
Copied contents to your clipboard!